Abstract
A recent report suggesting significant cost-effectiveness advantage for renal radiofrequency ablation (RFA) over partial nephrectomy makes assumptions about rates of local cancer recurrence, estimates of which are inexact at this point in time. Uncertainty regarding the oncologic efficacy of RFA technology and the expense and challenges of adequate post-treatment surveillance further confound this comparison. Partial nephrectomy remains the standard of care for nephron-sparing surgery, and should remain the preferred treatment in patients with an acceptable risk profile. Until longer-term follow-up data are available, RFA should be reserved for elderly patients and those with multiple comorbidities who have only a small renal mass.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
